Small-cell lung cancer (SCLC) has a particular propensity to metastasize to the brain, affecting 10% of SCLC patients at diagnosis, but may occur in more than 50% of 2-year survivors. Most cytotoxic drugs have limited ability to cross the blood-brain barrier, and the effectiveness of chemotherapy for brain metastasis is limited. Therefore, prophylactic cranial irradiation (PCI) has been proposed to treat SCLC. A meta-analysis revealed that PCI significantly decreased the risk of brain metastasis and increased the 3-year survival rate; it has been established as a standard therapy for limited-disease SCLC. However, certain aspects of PCI remain unclarified, including the roles in resected SCLC and extensive-disease SCLC, and its neurotoxicities. In addition, information on PCI has been obtained from old clinical trials without the use of new imaging devices, such as magnetic resonance imaging. Evidence from advanced imaging techniques is needed in this era.
Introduction
The risk of early hematogenous dissemination, marked sensitivity to chemotherapy and radiation, and a propensity to metastasize to the brain all distinguish small-cell lung cancer (SCLC) from non-smallcell lung cancer. The Veterans Administration Lung Study Group defines SCLC as either limited-disease SCLC (LD-SCLC) or extensivedisease SCLC (ED-SCLC). LD-SCLC includes tumors that can be encompassed in a single radiation port, and ED-SCLC includes tumors that extend beyond the boundaries of a single radiation port (1) . The standard initial therapy for LD-SCLC is concurrent chemoradiotherapy, and that for ED-SCLC is chemotherapy alone.
Brain metastasis is found in~10% of SCLC patients at diagnosis but may occur in more than 50% of 2-year survivors (2) . The effectiveness of chemotherapy for brain metastasis is limited because most cytotoxic drugs do not easily cross the blood-brain barrier. Consequently, in SCLC patients, the response rate of brain metastasis to systemic chemotherapy is only 27%, which is much lower than that of systemic lesions (73%) (3) . Because of improved success in the control of locoregional disease and distant metastasis, the proportion of SCLC patients with brain metastasis is increasing.
A number of clinical studies have been performed to evaluate prophylactic cranial irradiation (PCI) in SCLC, and many randomized trials have confirmed its effectiveness in reducing the incidence of brain metastasis. A meta-analysis concluded that PCI in LD-SCLC could achieve complete response (CR) to initial chemoradiotherapy and increase the 3-year survival rate. The clinical study evidence has thus established PCI as a standard therapy for LD-SCLC (4) .
In this review, we focus on the role of PCI in patients with SCLC.
Study search
The search for literature was conducted using PubMed. The following search terms were used for PubMed: 'small-cell lung cancer' and 'prophylactic cranial irradiation'. We selected studies that provided data on the overall survival (OS), incidence of brain metastasis and neurocognitive function. Only full articles be written in English were included. Studies with duplicate use of the same data were excluded. Of 727 articles that met the preliminary criteria, we finally included five meta-analyses, 10 randomized studies, seven nonrandomized studies and 10 retrospective studies.
PCI in patients with LD-SCLC
Many randomized trials have evaluated PCI in patients with SCLC, and some performed in the 1970 and 1980s reported that PCI significantly decreased the incidence of brain metastasis (5) . However, none of those studies showed the survival benefit of PCI, and most included very heterogeneous patient populations, including patients who could not achieve CR, those with LD-SCLC and ED-SCLC, and those treated with concomitant chemotherapy and differing PCI radiation doses. Furthermore, magnetic resonance imaging (MRI) was rarely used in those studies. MRI is more sensitive than computed tomography (CT) for detecting brain metastasis (6,7). Manapov et al. reported that asymptomatic brain metastasis was detected on MRI in 33% of the patients with initial LD-SCLC who had achieved CR to induction chemoradiotherapy (8) . Therefore, the previous studies may have included patients with asymptomatic brain metastasis, and the value of those studies is limited today.
Thereafter, some retrospective studies reported that PCI could not only decrease the incidence of brain metastasis but also prolong survival in patients who had achieved CR to initial treatment (9) (10) (11) . Therefore, randomized trials after the late 1980s included only patients with CR to induction treatment, and most found that PCI significantly decreased the incidence of brain metastasis. However, none of the trials individually showed a survival benefit of PCI (12) (13) (14) (15) (16) (17) .
In a meta-analysis performed by the Prophylactic Cranial Irradiation Overview Collaborative Group, data were evaluated from seven randomized trials including 987 SCLC patients who had achieved CR to induction treatment. That meta-analysis compared patients treated with PCI with patients treated without PCI. The primary endpoint was OS. The majority of patients (86%) had LD-SCLC; 14% had ED-SCLC. This analysis revealed that PCI significantly decreased the risk of brain metastasis from 58.8% to 33.3% at 3 years, and increased the 3-year survival rate from 15.3% in the control group to 20.7% (4).
Meert et al. published a systematic review of 12 randomized trials including 1547 patients (18) . Although those trials randomly decided which patients would and would not be treated with PCI, five trials included patients treated with PCI at initiation of chemotherapy and two included patients treated with PCI as consolidation treatment regardless of the initial treatment response. PCI significantly decreased the risk of brain metastasis, but unfortunately there was no significant between-group difference in OS. However, PCI did improve OS among patients who had achieved CR to induction treatment. The authors concluded that PCI could only be recommended for patients having achieved CR documented by a work-up including brain CT.
A retrospective study based on the National Cancer Institute's Surveillance, Epidemiology, and End Results Program by Patel et al. included 7995 patients and reported significantly longer OS in patients treated with PCI (42% at 2 years, 19% at 5 years and 9% at 10 years) than in those treated without PCI (23% at 2 years, 11% at 5 years and 6% at 10 years) (19) .
A single-center retrospective study by Giuliani et (20) .
From the results of such studies, PCI has been established as a part of the standard therapy for LD-SCLC patients who achieved CR to induction treatment.
PCI in patients with ED-SCLC
Only 14% of the patients included in the PCI Collaborative Group meta-analysis had ED-SCLC, and the role of PCI for patients with partial response (PR) to initial treatment remained unclear (4).
Slotman et al. and the European Organization for Research and Treatment of Cancer (EORTC) conducted a Phase III trial that randomly assigned 286 patients with ED-SCLC and PR or CR to initial treatment to receive PCI or not. PCI significantly decreased both the risk of symptomatic brain metastasis (HR, 0.27; 95% CI, 0.16-0.44; P < 0.001) and the cumulative risk of brain metastasis (from 40.4% to 14.6% at 1 year). Furthermore, PCI increased median OS from 5.4 to 6.7 months and 1-year OS from 13.3% to 27.1% (21) .
A pooled analysis of 318 patients with ED-SCLC and 421 patients with LD-SCLC who participated in four Phase II or III trials included 459 treated with PCI and 280 patients treated without PCI. In that analysis, Schild et al. found that the OS of patients treated with PCI was significantly longer than that of patients treated without PCI in both ED-SCLC (median OS, 10 vs. 8 months; HR, 0.77; P = 0.0282) and LD-SCLC (median OS, 17 vs. 14 months; HR, 0.68; P = 0.0045) (22) .
A randomized Phase III trial conducted in Japan included patients with ED-SCLC and any response to first-line chemotherapy and assigned them to either PCI (25 Gy/10 fractions) or no-PCI group. The planned sample size was 330 patients, and the primary endpoint was OS. The first interim analysis was performed in 163 patients; however, the enrollment of the patients was stopped because of lack of effect, and a total number of 224 patients were finally enrolled. PCI group had significantly reduced risk of brain metastasis compared no-PCI group (32.9% vs. 59.0% at 12 months; Gray's test, P < 0.001), but the median OS was 11.6 months in the former (n = 113) and 13.7 months in the latter (n = 111) (HR, 1.27; 95% CI, 0.96-1.68; two-sided log-rank test, P = 0.094). The authors concluded that PCI after a response to chemotherapy did not result in longer OS compared with observation in patients with ED-SCLC (23) .
It is possible that the difference in the results of those two randomized Phase III studies is due to the different inclusion criteria. In the EORTC study, brain CT or MRI before randomization was not required, and only symptomatic patients were evaluated with imaging studies. Conversely, all patients in the Japanese study underwent brain MRI before randomization to confirm the absence of brain metastasis, and they were followed up using brain MRI every 3 months. It is thus possible that the EORTC study only demonstrated the efficacy of whole-brain irradiation for known brain metastasis.
Because of these conflicting results, PCI for ED-SCLC remains controversial. The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Version 2.2017 give PCI for ED-SCLC a category 2A recommendation. The 2016 edition of the Japan Lung Cancer Society guidelines for the treatment of lung cancer does not recommend PCI for ED-SCLC (Grade D).
PCI in resected SCLC
Because few SCLC patients undergo surgery, to our knowledge, there are no randomized trials assessing the efficacy of PCI for patients with resected SCLC.
Eberhardt et al. reported that 35% of Stages IB-IIIB SCLC patients having undergone complete resection developed brain metastasis. This result showed that brain metastasis was one of the important causes of failure in completely resected SCLC (24) .
Several retrospective studies reported that the risk for development of brain metastasis was higher in more advanced stages. Gong et al. retrospectively analyzed resected SCLC patients (completely resected, 88.9%; incompletely resected, 11.1%), and reported that the frequency of brain metastasis at 5 years in patients with pathological Stages I, II and III was 6.25%, 28.2% and 29.1%, respectively (P = 0.026) (25) . Zhu et al. retrospectively analyzed patients with SCLC having undergone complete resection and reported that the frequency of brain metastasis at 3 years in patients with pathological Stages I, II and III was 9.7%, 18.5% and 35.4%, respectively (P = 0.013) (26) . On the basis of these results, the authors of those papers concluded that PCI may have a role for Stages II-III but not for Stage I in resected SCLC. Furthermore, Xu et al. analyzed 349 SCLC patients having undergone complete resection and reported longer OS in patient treated with PCI with than of the patients treated without PCI in pathological Stage II (HR, 0.54; 95% CI, 0.30-99; P = 0.047) and pathological Stage III (HR, 0.54; 95% CI, 0.34-86; P = 0.009). However, in pathological Stage I, neither OS nor the frequency of central nervous system recurrence differed significantly with and without PCI (27) .
By contrast, Tsuchiya et al. reported the results of prospective study analyzing 61 patients with completely resected SCLC who had undergone adjuvant chemotherapy but not received PCI (JCOG9101). The main site of first recurrence was the brain, and the overall frequency of brain metastasis in pathological Stage IA was 17% (28) .
Furthermore, the National Cancer Database study analyzing 1574 patients with pathological T1-2N0M0 completely resected SCLC reported that the OS of the patients with adjuvant chemotherapy was longer and cranial irradiation was lesser than that of patients without adjuvant therapy (HR, 0.52; 95% CI, 0.36-75; P < 0.01) (29) .
On the basis of these results, PCI has been adopted as part of the standard therapy for all patients with resected SCLC. However, there are not enough data supporting PCI for early-stage resected SCLC. The PCI for early-stage resected SCLC should be planned considering the balance between benefits and risks.
Timing of PCI
Auperin et al. performed a subgroup analysis of the abovementioned meta-analysis and showed that the incidence of brain metastasis was higher among patients who were randomized to PCI later after the start of induction therapy than in those who were randomized sooner (4). In contrast, OS was not affected by the timing of PCI. Ahles et al., however, reported that PCI delivered with chemotherapy damaged cognitive function (30) . These results suggest that PCI should be delivered soon after the start of induction therapy and should not be delivered in combination with chemotherapy (31).
Radiation dose of PCI
Gregor et al. conducted a three-arm randomized trial in 314 patients with LD-SCLC who achieved CR to induction therapy (16) . They were initially randomized to receive 36 Gy in 18 daily fractions (36 Gy/18 fr), 24 Gy in 12 fractions (24 Gy/12 fr), or no PCI. The protocol was subsequently amended to compare the clinician's choice of PCI regimen versus no PCI (3:2 ratio). According to the results of that study, PCI significantly reduced the appearance of brain metastasis, with an HR between the 24 Gy/12 fr and no-PCI groups of 0.71 (95% CI, 0.36-1.43) and an HR between the 36 Gy/ 18 fr and no-PCI groups of 0.16 (95% CI, 0.07-0.36). This demonstrated that higher doses of PCI could reduce brain metastasis.
This dose-response effect was also observed in a meta-analysis. In that meta-analysis, four dose groups (8 Gy, 24-25 Gy, 30 Gy and 36-40 Gy) were analyzed. The relative risk of brain metastasis in the 8, 24-25, 30 and 36-40 Gy groups compared with the no-PCI group was 0.76 (95% CI, 0.28-2.10), 0.52 (95% CI, 0.41-0.67), 0.34 (95% CI 0.41-0.67) and 0.27 (95% CI 0.14-0.51), respectively. There was a significant trend (P = 0.02) toward a lower risk of developing brain metastasis as the radiation dose increased. However, there was no significant trend (P = 0.89) between OS and total radiation dose (4).
Furthermore, Suwinski et al. reported the dose-response effect for reduction in brain relapse using the data collected from 12 randomized trials and 12 non-randomized trials on brain relapse rates with and without PCI (32) .
Le Pechoux et al. reported on an intergroup trial of 720 patients with LD-SCLC who achieved CR to induction therapy (33) . The patients were randomly assigned to receive 25 Gy in 10 daily fractions (25 Gy/10 fr) or a higher radiation dose (36 Gy in 18 daily fractions, or 36 Gy in 24 fractions over 16 days with two daily sessions of 1.5 Gy). There was no significant difference in the 2-year incidence of brain metastasis between the 25 Gy/10 fr group (29%; 95% CI, 24-35%) and the higher radiation dose group (23%; 95% CI, 18-29%) (HR, 0.80; 95% CI, 0.57-1.11; P = 0.18). However, 2-year OS was significantly higher in the 25 Gy/10 fr group (42%; 95% CI, 37-48%) compared with the higher radiation dose group (37%; 95% CI, 32-42%) (HR, 1.20; 95% CI, 1.00-1.44; P = 0.05). The lower OS in the higher-dose group was probably due to increased cancer-related mortality. In that trial, the dose-response effects for reduction in the incidence of brain metastasis and OS were not shown. The authors thus concluded that PCI at a total dose of 25 Gy should continue to be the standard of care in patients with LD-SCLC who respond well to initial treatments.
There are no adequate studies that evaluate the effect of fraction size in PCI. Some studies have reported PCI in small fractions appeared to be less neurotoxic (34) . On the basis of these results, 25 Gy/10 fr is considered to be the standard dose of PCI.
Neurotoxicity of PCI
Currently, studies evaluating the effect of PCI on neurocognitive function (NCF) and other quality-of-life (QOL) markers are limited, and the clinical significance of neurotoxicity following PCI remains controversial. Some previous studies concluded that PCI caused no significant neurotoxicity.
Grosshans et al. reported the results of neuropsychological tests conducted prospectively before and after PCI in 37 patients (mean age, 59 years). In that trial, neuropsychological testing focused on learning and memory (Verbal Selective Reminding Test and Benton Visual RetentionTest), executive function (Wisconsin Card Sorting, number of perseverative errors, and Trail Making Test Part B), verbal and visual reasoning (Similarities and Block Design subtests of the Wechsler Adult Intelligence Scale-Revised [WAIS-R]), attention (Digit Span and Arithmetic subtests of the WAIS-R), processing speed (Digit Symbol subtest of the WAIS-R and Trail Making Test Part A), expressive and receptive language (Controlled Oral Word Association and Token Test), and motor coordination (grip strength, grooved pegboard test, and finger tapping). The authors found no convincing evidence of any long-term PCI-related neurotoxic effects (median follow-up, 23 months; range, 6-120 months) (35) .
Arriagada et al. conducted a prospective study of 300 SCLC patients randomly assigned to receive (mean age, 57 years) or not receive PCI (mean age, 56 years). A neuropsychological examination and brain CT were performed at the time of random assignment and at 6, 18, 30 and 48 months (12) . In that study, the assessment included neurological tests (walking, standing up, muscular force, hypertonia, tendon reflexes, sensibility, cerebellar function and cranial nerves) and evaluation of higher brain functions (temporospatial orientation, memory, judgment, language, praxis and mood status). There were no significant differences between the two groups in neuropsychological function or abnormalities on brain CT.
In contrast, however, other studies concluded that PCI possibly decreased NCF. Gondi et al. reported the results of a pooled secondary analysis of two Radiation Therapy Oncology Group (RTOG) trials (36) . In those trials, self-reported cognitive functioning (SRCF) was assessed prospectively using the EORTC QLQ-C30 at baseline (after locoregional therapy but before PCI or observation) and at 6 and 12 months. The EORTC QLQ-C30 is a 30-item self-report questionnaire containing multiple QOL scales (37) . Furthermore, cognitive function was tested with the Hopkins Verbal Learning Test (HVLT) at baseline and at 6 and 12 months in those trials. The HVLT involves memorizing a list of 12 nouns for three consecutive trials (Recall) and recalling the 12 nouns after a 20-min delay (Delayed Recall) (38) . In the pooled analysis, all patients who developed an intracranial relapse before follow-up evaluation were excluded, and PCI was associated with a higher risk of decline in SRCF and in HVLT-Recall and -Delayed Recall at 6 and 12 months. The median age of the patients analyzed was 62 years, and age >60 years was associated with higher rates of HVLT-Delayed Recall decline at 12 months. Moreover, Welzel et al. reported a prospective study analyzing radiation-induced change in the white matter after PCI in patients with SCLC. In that study, fractional anisotropy (FA) was evaluated with diffusion tensor imaging and conventional T2-weighted MRI. Measurements of FA were performed before, at the end of, and 6 weeks after PCI. FA decreased significantly in supratentorial and infratentorial normal-appearing white matter from the beginning to the end of PCI. A further decline in FA occurred 6 weeks after PCI. The authors also reported that patients aged ≥65 years showed a trend toward a stronger reduction in FA (39).
Seto et al. recently reported the results of cognitive function tests in a Japanese randomized Phase III trial investigating the efficacy of PCI in ED-SCLC. Cognitive function was assessed using the Mini Mental State Examination (MMSE) before and 12 and 24 months after randomization. The MMSE is an 11-question assessment that tests five areas of cognitive function: orientation, registration, attention and calculation, recall, and language. Physicians administered the questionnaire in person. They found no significant difference between the PCI and no-PCI groups among all patients, but the MMSE score tended to decline in the PCI group among patients aged ≥70 years (40) .
Although the abovementioned studies failed to provide conclusive evidence regarding the neurotoxicity of PCI, we cannot rule out the possibility that PCI may have neurotoxic effects, particularly in older patients. The planning of treatment for SCLC in older patients should thus take account of the balance between the benefits and risks of treatment modalities. Furthermore, we need prospective studies including long-term follow-up of patients (41) .
Neurotoxicity from whole-brain irradiation may be caused by damage to neural progenitor cells in the subventricular zone and hippocampus and neuroinflammation in the brain (42, 43) . In consideration of the low frequency of brain metastasis in the hippocampal region, reducing the radiation dose to the hippocampus during whole-brain radiotherapy (WBRT) could prevent decline in neurocognitive function. A Phase II trial of brain metastasis by Gondi et al. showed that conformal avoidance of the hippocampus during WBRT was associated with preservation of memory and QOL as compared with historical control (44) . There are several ongoing Phase III trials assessing SCLC treated with PCI with or without hippocampal sparing (NCT01780675, NCT02397733 and NCT02635009). The primary endpoint of these trials is neurocognitive function.
Conclusion
PCI has been established as part of the standard therapy for resected SCLC and LD-SCLC patients who achieved CR to induction treatment. Conversely, its use is still controversial for ED-SCLC. We should deliver PCI earlier after the induction therapy and should not deliver PCI in combination with chemotherapy. In PCI, 25 Gy/10 fr is considered to be the standard dose. It is unclear if neurotoxicity occurs due to PCI, but we cannot rule out this possibility, particularly in older patients. Therefore, we need prospective studies including long-term follow-up of patients. The information on PCI has been obtained from old clinical trials without the use of new imaging diagnostic devices, such as MRI. New data are warranted in the modern era.
